Thomas A Rasmussen1, Martin Tolstrup2, Christel R Brinkmann2, Rikke Olesen2, Christian Erikstrup3, Ajantha Solomon4, Anni Winckelmann2, Sarah Palmer5, Charles Dinarello6, Maria Buzon7, Mathias Lichterfeld7, Sharon R Lewin8, Lars Østergaard2, Ole S Søgaard2. 1. Department of Infectious Diseases, Aarhus University Hospital, Denmark. Electronic address: thomrasm@rm.dk. 2. Department of Infectious Diseases, Aarhus University Hospital, Denmark. 3. Department of Clinical Immunology, Aarhus University Hospital, Denmark. 4. Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC, Australia. 5. Westmead Millennium Institute for Medical Research, University of Sydney, Westmead, NSW, Australia. 6. Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, CO, USA. 7. Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA; Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA. 8. Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC, Australia; Centre for Biomedical Research, Burnet Institute, Melbourne, VIC, Australia.
Abstract
BACKGROUND: Activating the expression of latent virus is an approach that might form part of an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to disrupt HIV-1 latency and the safety of this strategy. METHODS: In this phase 1/2 clinical trial, we included aviraemic adults with HIV treated at Aarhus University Hospital, Denmark. Participants received oral panobinostat (20 mg) three times per week every other week for 8 weeks while maintaining combination antiretroviral therapy. The primary outcome was change from baseline of cell-associated unspliced HIV RNA. Secondary endpoints were safety, plasma HIV RNA, total and integrated HIV DNA, infectious units per million CD4 T cells, and time to viral rebound during an optional analytical treatment interruption of antiretroviral therapy. This trial is registered with ClinicalTrial.gov, number NCT01680094. FINDINGS: We enrolled 15 patients. The level of cell-associated unspliced HIV RNA increased significantly at all timepoints when patients were taking panobinostat (p < 0·0001). The median maximum increase in cell-associated unspliced HIV RNA during panobinostat treatment was 3·5-fold (range 2·1-14·4). Panobinostat induced plasma viraemia with an odds ratio of 10·5 (95% CI 2·2-50·3; p = 0·0002) compared with baseline. We recorded a transient decrease in total HIV DNA, but no cohort-wide reduction in total HIV DNA, integrated HIV DNA, or infectious units per million. Nine patients participated in the analytical treatment interruption, median time to viral rebound was 17 days (range 14-56). Panobinostat was well tolerated. 45 adverse events were reported, but only 16 (all grade 1) were presumed related to panobinostat. INTERPRETATION: Panobinostat effectively disrupts HIV latency in vivo and is a promising candidate for future combination clinical trials aimed at HIV eradication. However, panobinostat did not reduce the number of latently infected cells and this approach may need to be combined with others to significantly affect the latent HIV reservoir. FUNDING: The Danish Council for Strategic Research and Aarhus University.
BACKGROUND: Activating the expression of latent virus is an approach that might form part of an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to disrupt HIV-1 latency and the safety of this strategy. METHODS: In this phase 1/2 clinical trial, we included aviraemic adults with HIV treated at Aarhus University Hospital, Denmark. Participants received oral panobinostat (20 mg) three times per week every other week for 8 weeks while maintaining combination antiretroviral therapy. The primary outcome was change from baseline of cell-associated unspliced HIV RNA. Secondary endpoints were safety, plasma HIV RNA, total and integrated HIV DNA, infectious units per million CD4 T cells, and time to viral rebound during an optional analytical treatment interruption of antiretroviral therapy. This trial is registered with ClinicalTrial.gov, number NCT01680094. FINDINGS: We enrolled 15 patients. The level of cell-associated unspliced HIV RNA increased significantly at all timepoints when patients were taking panobinostat (p < 0·0001). The median maximum increase in cell-associated unspliced HIV RNA during panobinostat treatment was 3·5-fold (range 2·1-14·4). Panobinostat induced plasma viraemia with an odds ratio of 10·5 (95% CI 2·2-50·3; p = 0·0002) compared with baseline. We recorded a transient decrease in total HIV DNA, but no cohort-wide reduction in total HIV DNA, integrated HIV DNA, or infectious units per million. Nine patients participated in the analytical treatment interruption, median time to viral rebound was 17 days (range 14-56). Panobinostat was well tolerated. 45 adverse events were reported, but only 16 (all grade 1) were presumed related to panobinostat. INTERPRETATION:Panobinostat effectively disrupts HIV latency in vivo and is a promising candidate for future combination clinical trials aimed at HIV eradication. However, panobinostat did not reduce the number of latently infected cells and this approach may need to be combined with others to significantly affect the latent HIV reservoir. FUNDING: The Danish Council for Strategic Research and Aarhus University.
Authors: Mary F Kearney; Ann Wiegand; Wei Shao; John M Coffin; John W Mellors; Michael Lederman; Rajesh T Gandhi; Brandon F Keele; Jonathan Z Li Journal: J Virol Date: 2015-11-18 Impact factor: 5.103
Authors: Alexander O Pasternak; Laura K DeMaster; Neeltje A Kootstra; Peter Reiss; Una O'Doherty; Ben Berkhout Journal: J Virol Date: 2015-11-11 Impact factor: 5.103
Authors: Ross A Pollack; R Brad Jones; Mihaela Pertea; Katherine M Bruner; Alyssa R Martin; Allison S Thomas; Adam A Capoferri; Subul A Beg; Szu-Han Huang; Sara Karandish; Haiping Hao; Eitan Halper-Stromberg; Patrick C Yong; Colin Kovacs; Erika Benko; Robert F Siliciano; Ya-Chi Ho Journal: Cell Host Microbe Date: 2017-04-12 Impact factor: 21.023
Authors: Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis Journal: J Clin Invest Date: 2017-07-17 Impact factor: 14.808
Authors: Nina C Flerin; Ariola Bardhi; Jian Hua Zheng; Maria Korom; Joy Folkvord; Colin Kovacs; Erika Benko; Ronald Truong; Talia Mota; Elizabeth Connick; R Brad Jones; Rebecca M Lynch; Harris Goldstein Journal: J Virol Date: 2019-03-05 Impact factor: 5.103